Analysts expect that Endocyte, Inc. (NASDAQ:ECYT) will post ($0.16) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Endocyte’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.16). Endocyte reported earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year-over-year growth rate of 38.5%. The firm is scheduled to report its next quarterly earnings results on Friday, March 9th.
On average, analysts expect that Endocyte will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.23). For the next financial year, analysts expect that the company will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Endocyte.
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The firm had revenue of $0.03 million during the quarter. During the same quarter last year, the company posted ($0.21) earnings per share. Endocyte’s quarterly revenue was up .0% on a year-over-year basis.
In related news, insider Philip S. Low bought 5,600 shares of Endocyte stock in a transaction dated Monday, November 13th. The shares were bought at an average cost of $4.84 per share, with a total value of $27,104.00. Following the acquisition, the insider now owns 283,005 shares in the company, valued at approximately $1,369,744.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.86% of the company’s stock.
Several hedge funds have recently made changes to their positions in ECYT. Dimensional Fund Advisors LP lifted its position in shares of Endocyte by 34.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares during the last quarter. Spark Investment Management LLC bought a new stake in shares of Endocyte during the 2nd quarter worth $177,000. LMR Partners LLP bought a new stake in shares of Endocyte during the 2nd quarter worth $196,000. Bank of New York Mellon Corp lifted its position in shares of Endocyte by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 6,469 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Endocyte by 284.4% during the 1st quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 142,461 shares during the last quarter. Institutional investors and hedge funds own 17.67% of the company’s stock.
Endocyte (ECYT) opened at $5.12 on Friday. Endocyte has a 1-year low of $1.17 and a 1-year high of $6.55.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Endocyte Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endocyte Inc. and related companies.